叉头框蛋白Q1对肝细胞癌患者术后行经肝动脉化疗栓塞术疗效的影响

周益龙; 陈橼; 张一心; 邵冰峰; 张素青; 徐爱兵; 何松; 李拥军; 田思源

doi:10.3969/j.issn.1001-5256.2016.11.024

叉头框蛋白Q1对肝细胞癌患者术后行经肝动脉化疗栓塞术疗效的影响

DOI: 10.3969/j.issn.1001-5256.2016.11.024

1. 南通大学附属肿瘤医院外科
2. 南通大学附属肿瘤医院肝肿瘤介入科
3. 南通大学附属肿瘤医院病理科

基金项目:

江苏省南通市卫生青年基金资助项目(WQ2015047)；江苏省南通市科技计划指导性项目(YYZ15006)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1999
- HTML全文浏览量: 10
- PDF下载量: 407
- 被引次数: 0
出版历程
- 出版日期: 2016-11-20

Influence of Forkhead box Q1 expression on therapeutic effect of transarterial chemoembolization after hepatocellular carcinoma surgery

Research funding:

摘要

摘要: 目的研究叉头框蛋白Q1（FOXQ1）在肝细胞癌（HCC）组织中的表达情况,探讨其对手术切除后行经肝动脉化疗栓塞术预后的影响,分析FOXQ1在评估肝癌疗效中的价值。方法收集2004年1月-2007年12月南通大学附属肿瘤医院收治的HCC患者120例。采用免疫组化分析FOXQ1在HCC组织中的表达情况,与患者临床特征进行比较。计数资料组间比较采用χ2检验;利用Kaplan-Meier曲线和log-rank分析患者术后的无瘤生存率（DFS）;采用Cox比例风险回归模型进行单因素和多因素回归分析。结果免疫组化结果显示,FOXQ1在癌组织中呈深褐色,主要表达于肿瘤细胞质和细胞核中。单因素回归分析结果显示患者术后5年的DFS受肝脏TNM分期[风险比（HR）=0.347,95%可信区间（95%CI）:0.2100.573,P<0.001]、肝内肿瘤个数（HR=0.294,95%CI:0.1760.490,P<0.001）、HBV感染情况（HR=0.395,95%CI:0.2220.704,P=0.002）、AFP表达水平（...
- 癌,肝细胞 /
- 叉头转录因子类 /
- 化学栓塞,治疗性
Abstract: Objective To investigate the expression of Forkhead box Q1( FOXQ1) in the tissue of hepatocellular carcinoma( HCC),its influence on the prognosis of surgical resection combined with transarterial chemoembolization( TACE),and the value of FOXQ1 in evaluating the treatment outcome of HCC. Methods A total of 120 HCC patients who were admitted to The Affiliated Tumor Hospital of Nantong University from January 2004 to December 2007 were enrolled. Immunohistochemistry was used to measure the expression of FOXQ1 in HCC tissue,which was compared with patients' clinical features. The chi- square test was used for comparison of categorical data between groups,the Kaplan- Meier curve and log- rank test were used to analyze patients' disease- free survival( DFS) rates after surgery,and the Cox proportional hazards regression model was used for univariate and multivariate regression analyses. Results The results of immunohistochemistry showed that FOXQ1 had a dark- brown color in HCC tissue and was mainly expressed in tumor cytoplasm and nucleus. The univariate regression analysis showed that patients' DFS was affected by TNM stage( HR = 0. 347,95% CI: 0. 210- 0. 573,P < 0. 001),the number of tumors in the liver( HR = 0. 294,95% CI: 0. 176- 0. 490,P < 0. 001),HBV infection( HR = 0. 395,95% CI: 0. 222-0. 704,P = 0. 002),alpha- fetoprotein expression( HR = 0. 348,95% CI: 0. 207- 0. 586,P < 0. 001),presence or absence of liver cirrhosis( HR = 0. 414,95% CI: 0. 244- 0. 702,P = 0. 001),and high FOXQ1 expression level( HR = 1. 968,95% CI: 1. 171- 3. 308,P = 0. 011). Multivariate regression analysis showed that the patents' DFS was associated with TNM stage( HR = 0. 466,95% CI: 0. 248-0. 874,P = 0. 017),the number of tumors in the liver( HR = 0. 427,95% CI: 0. 216- 0. 844,P = 0. 014),and high FOXQ1 expression level( HR = 2. 896,95% CI: 1. 628- 5. 152,P < 0. 001). The patients with a high FOXQ1 expression level had a shorter DFS than those with a low FOXQ1 expression level( 18 months vs 26 months,χ2= 5. 006,P = 0. 025). Conclusion FOXQ1 can be used as a biomarker to evaluate the prognosis of HCC patients and the treatment outcome of HCC.
- carcinoma,hepatocellular /
- forkhead transcription factors /
- chemoembolization,therapeutic

HTML全文

参考文献(14)

[1]WANG W,HE S,JI J,et al.The prognostic significance of FOXQ1 oncogene overexpression in human hepatocellular carcinoma[J].Pathol Res Pract,2013,209(6):353-358.

[2]KANEDA H,ARAO T,TANAKA K,et al.FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth[J].Cancer Res,2010,70(5):2053-2063.

[3]ZHANG H,MENG F,LIU G,et al.Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis[J].Cancer Res,2011,71(4):1292-1301.

[4]XIA L,HUANG W,TIAN D,et al.Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV 1 expression[J].Hepatology,2014,59(3):958-973.

[5]FENG J,ZHANG X,ZHU H,et al.Fox Q1 overexpression influences poor prognosis in non-small cell lung cancer,associates with the phenomenon of EMT[J].PLoS One,2012,7(6):e39937.

[6]PENG X,LUO Z,KANG Q,et al.FOXQ1 mediates the crosstalk between TGF-βand Wnt signaling pathways in the progression of colorectal cancer[J].Cancer Biol Ther,2015,16(7):1099-1109.

[7]FENG J,XU L,NI S,et al.Involvement of Fox Q1 in NSCLC through regulating EMT and increasing chemosensitivity[J].Oncotarget,2014,5(20):9689-9702.

[8]YAMAKADO K,HIROTA S.Sub-classification of intermediate-stage(Barcelona Clinic Liver Cancer stage-B)hepatocellular carcinomas[J].World J Gastroenterol,2015,21(37):10604-10608.

[9]ZHOU YL,SHAO BF,SHI DH,et al.Association between PET-CT imaging and tumor pathological classification in hepatocellular carcinoma[J].J Nantong Univ:Med Sci,2012,32(5):391-393.(in Chinese)周益龙,邵冰峰,施冬辉,等.肝细胞肝癌PET-CT显像与肿瘤病理分级的相关性研究[J].南通大学学报:医学版,2012,32(5):391-393.

[10]ZHOU YL SHAO BF,XU AB,et al.Value of indocyanine green retention rate at 15 minutes in surgical treatment of resectable liver cancer after multiple transarterial chemoembolization treatments[J].J Nantong Univ:Med Sci,2012,35(4):295-297.(in Chinese)周益龙,邵冰峰,徐爱兵,等.ICGR15在多次肝动脉栓塞化疗后的可切除性肝癌外科治疗中的意义[J].南通大学学报:医学版,2012,35(4):295-297.

[11]CHENG HY.Interventional treatment for hepatocellular carcinoma:a review of current status and perspectives[J].J Clin Hepatol,2016,32(1):3-8.(in Chinese)程红岩.肝癌介入治疗的现状与展望[J].临床肝胆病杂志,2016,32(1):3-8.

[12]MA SJ,ZOU SJ,LUO XL,et al.Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J].J Clin Hepatol,2016,32(1):80-83.(in Chinese)马士杰,邹绍静,罗小玲,等.经肝动脉化疗栓塞术治疗肝细胞癌的预后影响因素分析[J].临床肝胆病杂志,2016,32(1):80-83.

[13]FENG M,E CY,LI H,et al.Expression of miR-196a in liver cancer cells and its promotion effect on proliferation[J].J Jilin Univ:Med Edit,2015,41(1):120-124.(in Chinese)冯默,鄂长勇,李航,等.miR-196a在肝癌细胞中的表达及其促增殖作用[J].吉林大学学报:医学版,2015,41(1):120-124.

[14]QIN J,XU Y,LI X,et al.Effects of lentiviral-mediated Foxp1 and Foxq1 RNAi on the hepatocarcinoma cell[J].Exp Mol Pathol,2014,96(1):1-8.

施引文献

资源附件(0)

访问统计